No profile data available.
Repligen Corporation (RGEN) is a healthcare company in the biological analysis equipment industry, based in Waltham, United States, with about 2,000 full-time employees.
It reported revenue of $738.26 million for fiscal year 2025, up 16.4% from fiscal year 2024, and net income of $48.89 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $204.13 million, up 11.9% from a year before. North America was its largest region in fiscal year 2025, with 49% of revenue. Its market capitalization was $11.04 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
Repligen reported $738.26 million in revenue for fiscal year 2025, up 16.4% from $634.44 million in fiscal year 2024. In Q2 2026 revenue was $204.13 million.
North America: 49% of revenue by region in fiscal year 2025, followed by Europe (34%).
$11.04 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (biological analysis equipment) include Mettler-Toledo International Inc. (MTD), Revvity, Inc. (RVTY), Bio-Techne Corporation (TECH), Twist Bioscience Corporation (TWST).